Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01924754 · ClinicalTrials.gov registry record
Gardasil Immunogenicity With Needle-Free Injection
A clinical trial of HPV Seroconversion, sponsored by University of California, San Francisco.
- Completed
- Registry status
- 150
- Enrollment target
- 2
- Study locations
NCT01924754: Completed study of HPV Seroconversion, sponsored by University of California, San Francisco.
NCT01924754 is a study of HPV Seroconversion that has completed, run by University of California, San Francisco. The registered enrollment target is 150 participants. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01924754, a study of HPV Seroconversion, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- 150 participants
- Enrollment target
- 2
- Study locations
Study Summary
Using biospecimens collected in a trial by the Thai Red Cross AIDS Research Center that studied two new human papillomavirus (HPV) vaccine delivery regimens, the investigators at UCSF will be testing the serum for antibodies to measure the strength of their response to the vaccine.
Primary Outcome
Geometric mean antibody concentrations above the lower limit of assay detection at baseline were assessed by HPV type
Conditions Studied
Study Locations (2)
California
- University of California, San Francisco - San Francisco
Other
- Thai Red Cross AIDS Research Centre - Bangkok
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2014-01-01 |
| Est. Completion | 2016-05-31 |
What the finished NCT01924754 record still lists
NCT01924754 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with HPV Seroconversion appearing as the primary indexed condition, and to 0 interventions.
NCT01924754 reports a single indexed study location in California, Other.
Frequently Asked Questions
What is clinical trial NCT01924754 about?
NCT01924754 is a clinical study titled "Gardasil Immunogenicity With Needle-Free Injection". Using biospecimens collected in a trial by the Thai Red Cross AIDS Research Center that studied two new human papillomavirus (HPV) vaccine delivery regimens, the investigators at UCSF will be testing the serum for antibodies to measure the strength of their response to the vaccine.
What is the current status of trial NCT01924754?
This trial is currently completed. The enrollment target is 150 participants. The study started on 2014-01-01. Estimated completion is 2016-05-31.
What conditions does trial NCT01924754 study?
This clinical trial studies the following conditions: HPV Seroconversion.
Who is sponsoring clinical trial NCT01924754?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01924754 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI